Quarterly ResultApr 30, 2026, 07:12 AM
BCYC Q1 Net Loss $60.8M; Strategic Reprioritization & 30% Workforce Cut
AI Summary
Bicycle Therapeutics reported a Q1 2026 net loss of $60.8 million and announced a strategic reprioritization, including a 30% workforce reduction. This restructuring is expected to reduce annual operating expenses by approximately 50% and extend the company's cash runway into 2030. The company also provided positive updates on its EphA2 targeting drug conjugate, nuzefatide pevedotin, advancing it to Phase 2 for pancreatic cancer, while deprioritizing zelenectide pevedotin for internal development.
Key Highlights
- Strategic reprioritization initiated, including a ~30% workforce reduction.
- Expected annual operating expense reduction of ~50% and cash runway extended into 2030.
- Nuzefatide pevedotin Phase 1/2 data showed 40% ORR in EphA2+ mUC; Phase 2 for pancreatic cancer initiated.
- Zelenectide pevedotin program deprioritized for internal development; Duravelo-2 trial converted to randomized Phase 2.
- Q1 2026 net loss was $60.8 million, compared to $60.8 million in Q1 2025.
- Cash and cash equivalents were $559.5 million as of March 31, 2026.
- Collaboration revenue decreased to $0.9 million in Q1 2026 from $10.0 million in Q1 2025.
- R&D expenses decreased to $48.9 million in Q1 2026 from $59.1 million in Q1 2025.